Home » Business News » 2012 » September » September 14, 2012

PropThink: Pluristem Raises Money Through Equity Offering; Will Momentum Continue?

September 14, 2012 -

Pluristem Therapeutics (NASDAQ:PSTI) gapped down 15% Thursday morning after an announcement that the company will be raising capital through the sale of $32M in common stock and warrants. The company will sell 8M units - each unit consisting of one share of common stock and a warrant to purchase 0.35 shares of the stock- at $4 a piece. Shares are, however, already rebounding slightly in the late morning as investors are still interested in Pluristem's proprietary placental cell-based therapies. Shares of the company have more than doubled in the last six months, and closed Wednesday, before the financing announcement, at $4.54. PSTI's visibility improved drastically in July - average volume more than quadrupled - after a series of bullish articles were published on Seeking Alpha.
On August 30th, Pluristem filed for Orphan Drug Status in treating aplastic anemia with its PLacental eXpanded (PLX) cells, setting the stage for a catalyst if the treatment receives approval in the next few months. The company also commenced with a phase II trial of PLX cells to treat intermittent claudication in August. PSTI should remain weak through the day, however the question is whether or not increased visibility and volume in the last two months will continue after Thursday's losses. If so, bullish sentiment will help buoy shares relatively quickly. Otherwise, it may not be until PSTI receives orphan drug approval that shares strengthen significantly.
Click here to see this article at
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on To learn more, follow us on Twitter or visit us at

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE


Copyright 2012 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

ACN Newswire

Comment on this story